Peter A. Hruskoci

Array ( [id] => 17642258 [patent_doc_number] => 20220169996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => TRUNCATED ACTRIIB-FC FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/358540 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370010 [patent_doc_number] => 20220025062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/358642 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467672 [patent_doc_number] => 11274140 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/346095 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 60335 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399630 [patent_doc_number] => 20220041720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Methods and Compositions for Preventing Type 1 Diabetes [patent_app_type] => utility [patent_app_number] => 17/345495 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17345495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256118 [patent_doc_number] => 12428461 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Treating cancer with a conjugate comprising an IL-2 moiety [patent_app_type] => utility [patent_app_number] => 17/997363 [patent_app_country] => US [patent_app_date] => 2021-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98290 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19164773 [patent_doc_number] => 11980655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-14 [patent_title] => Methods of treatment with stable liquid formulations of glucagon-like peptide 1 or analogues thereof [patent_app_type] => utility [patent_app_number] => 17/334419 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37183 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17334419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449603 [patent_doc_number] => 20230190879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/927304 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451522 [patent_doc_number] => 20230192800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/927150 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256830 [patent_doc_number] => 20210369815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => GLUCOSE RESPONSIVE INSULINS [patent_app_type] => utility [patent_app_number] => 17/327498 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521116 [patent_doc_number] => 12122824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis [patent_app_type] => utility [patent_app_number] => 17/320490 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 61141 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 294 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420148 [patent_doc_number] => 20230174609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => EXTENDED TIME ACTION ACYLATED INSULIN COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/998090 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142268 [patent_doc_number] => 20230016112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => ENGINEERED CD25 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/320118 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717359 [patent_doc_number] => 12202882 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/315168 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 60255 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505457 [patent_doc_number] => 20220098559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => ISOLATED GDF TRAP POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 17/243049 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19042345 [patent_doc_number] => 11931418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Methods of treating severe inflammation [patent_app_type] => utility [patent_app_number] => 17/240558 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 2 [patent_no_of_words] => 17419 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020929 [patent_doc_number] => 20210244800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => Use of Ultrarapid Acting Insulin [patent_app_type] => utility [patent_app_number] => 17/240802 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240802 [rel_patent_id] =>[rel_patent_doc_number] =>)